Carcinoid Heart Disease: Early Outcomes after Surgical Valve Replacement in Nine Patients

Authors

  • Syed Saleem Mujtaba Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom
  • Stephen Clark Department of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom

DOI:

https://doi.org/10.1532/hsf.1855

Keywords:

Carcinoid heart disease, valve replacement, valve stenosis, valve regurgitation

Abstract

Aim: To describe the early outcomes of carcinoid patients undergoing surgical heart valve replacement.

Methods: In a retrospective study, records of patients with symptomatic carcinoid heart disease referred for valve surgery between 2012 and 2016 were reviewed. The perioperative and early postoperative outcomes were analyzed.

Results: Nine patients, with a mean age of 61 years (range 55-70 years) underwent cardiac surgery for carcinoid syndrome. 3 patients had quadruple valve replacement, 5 had tricuspid and pulmonary valves changed, while one had tricuspid, pulmonary, and aortic valves replaced. Right-sided valves were replaced with biological valves in 8 patients and a mechanical valve in 1 patient. Left-sided valves were replaced with a mechanical valve in 2 patients and with a biological valve in 1 patient. Mean postoperative follow-up was 24 months (range 6-50 months, median 16 months). All patients had a good left ventricle except one, in whom it was mildly impaired. The right ventricle was severely dilated in 4 patients, moderately in 2, and mildly in 3. One patient died of heart failure 10 days postoperatively. Functional improvement was noted in all survivors, and they were in New York Heart Association class I at last follow up.

Conclusion: Although carcinoid syndrome is a rare and progressive disease, valve replacement in symptomatic patients is a reasonable option with survival benefit, low early postoperative mortality, without valve-related complications, and with functional improvement. Cardiac assessment is required in all patients with carcinoid disease from the earliest time of medical treatment to improve patients’ result.

References

Arghani A, Connolly HM, Abel MD, Schaff HV. 2010. Quadruple valve replacement in patients with carcinoid heart disease. J Thoracic Cardiovasc Surg 140:1432-4.

Bernheim AM, Connolly HM, Hobday TJ, Abel MD, Pellikka PA. 2007. Carcinoid heart disease. Prog Carciovasc Dis 49:439-51.

Bhattacharyya S, Raja SG, Toumpanakis C, Caplin ME, Dreyfus GD, Davar J. 2011. Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg 40:168-72.

Castillo JG, Filsoufi F, Rahmanian PB, et al. 2008. Early and late results of valvular surgery for carcinoid heart disease. J Am Coll Cardiol 51:1507-9.

Castillo JG, Filsoufi F, Rahmanian PB, et al. 2008. Early and late results of valvular surgery for carcinoid heart disease. J Am Coll Cardiol 51:1507-9.

Connolly HM. 2001. Carcinoid heart disease: medical and surgical considerations. Cancer control 8:454-60.

Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD, Pellikka PA. 2001. Surgical management of left-sided carcinoid heart disease. Circulation 104:12 (Suppl. 1):I36-I40

Connolly HM, Schaff HV, Mullany CJ, Abel MD, Pellikka PA. 2002. Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation 106(suppl):I51-6.

Ferrans V, Roberts W. 1976. The carcinoid endocardial plaque: an ultrastructural study. Hum Pathol 7:387-409.

Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin IM. 2008. Carcinoid heart disease. Int J Cardiol 129:318-24.

Komoda S, Komoda T, Pavel ME, et al. 2011. Cardiac surgery for carcinoid heart disease in 12 cases. Gen Thorac Cardiovasc Surg 59:780-5.

McDonald ML, Nagorney DM, Connolly HM, Nishimura RA, Schaff HV. 1999. Carcinoid heart disease and carcinoid syndrome: successful surgical treatment. Ann Thorac Surg 67:537-9.

Moertel C. Karnofsky memorial lecture. 1987. An odyssey in the land of small tumors. J Clin Oncol 5:1502-22.

Pellikka P, Tajik A, Khandheria B, et al. 1993. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation 87:1188-96.

Raja SG, Bhattacharyya S, Davar J, Dreyfus GD. 2010. Surgery for carcinoid heart disease: current outcomes, concerns and controversies. Future Cardiol 6:647-55.

Ridker PM, Chertow GM, Karlson EW, Neish AS, Schoen FJ. 1991. Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. Am Heart J 121:1835-8.

Roberts W. 1997. A unique heart disease associated with a unique cancer: carcinoid heart disease. Am J Cardiol 80:251-6.

Takahashi H, Okada K, Asano M, Matsumori M, Morimoto Y, Okita Y. 2009. Bioprosthetic pulmonary and tricuspid valve replacement in carcinoid heart disease from ovarian primary cancer. Circ J 73:1554-6.

Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, Tinteren H, Taal BG. 2003. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 97:1609-15.

Published

2018-02-16

How to Cite

Mujtaba, S. S., & Clark, S. (2018). Carcinoid Heart Disease: Early Outcomes after Surgical Valve Replacement in Nine Patients. The Heart Surgery Forum, 21(1), E040-E043. https://doi.org/10.1532/hsf.1855

Issue

Section

Articles